AYTU vs. TPST, CGTX, PASG, CYTH, DRRX, KALA, CALC, GRCE, TENX, and LIAN
Should you be buying Aytu BioPharma stock or one of its competitors? The main competitors of Aytu BioPharma include Tempest Therapeutics (TPST), Cognition Therapeutics (CGTX), Passage Bio (PASG), Cyclo Therapeutics (CYTH), DURECT (DRRX), KALA BIO (KALA), CalciMedica (CALC), Grace Therapeutics (GRCE), Tenax Therapeutics (TENX), and LianBio (LIAN). These companies are all part of the "pharmaceutical products" industry.
Aytu BioPharma vs.
Aytu BioPharma (NASDAQ:AYTU) and Tempest Therapeutics (NASDAQ:TPST) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, community ranking, risk, profitability, valuation, dividends, institutional ownership, earnings and media sentiment.
Aytu BioPharma has higher revenue and earnings than Tempest Therapeutics. Aytu BioPharma is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks.
Tempest Therapeutics has a net margin of 0.00% compared to Aytu BioPharma's net margin of -7.62%. Aytu BioPharma's return on equity of -19.30% beat Tempest Therapeutics' return on equity.
In the previous week, Tempest Therapeutics had 14 more articles in the media than Aytu BioPharma. MarketBeat recorded 15 mentions for Tempest Therapeutics and 1 mentions for Aytu BioPharma. Aytu BioPharma's average media sentiment score of 0.94 beat Tempest Therapeutics' score of 0.05 indicating that Aytu BioPharma is being referred to more favorably in the media.
Aytu BioPharma has a beta of 0.07, meaning that its stock price is 93% less volatile than the S&P 500. Comparatively, Tempest Therapeutics has a beta of -2.34, meaning that its stock price is 334% less volatile than the S&P 500.
Aytu BioPharma received 153 more outperform votes than Tempest Therapeutics when rated by MarketBeat users. Likewise, 67.11% of users gave Aytu BioPharma an outperform vote while only 65.38% of users gave Tempest Therapeutics an outperform vote.
Tempest Therapeutics has a consensus price target of $30.00, indicating a potential upside of 313.79%. Given Tempest Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Tempest Therapeutics is more favorable than Aytu BioPharma.
33.5% of Aytu BioPharma shares are held by institutional investors. Comparatively, 22.5% of Tempest Therapeutics shares are held by institutional investors. 2.8% of Aytu BioPharma shares are held by company insiders. Comparatively, 4.7% of Tempest Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Summary
Aytu BioPharma beats Tempest Therapeutics on 11 of the 17 factors compared between the two stocks.
Get Aytu BioPharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for AYTU and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aytu BioPharma Competitors List
Related Companies and Tools
This page (NASDAQ:AYTU) was last updated on 4/16/2025 by MarketBeat.com Staff
